Analyse and benchmark your data using an established global registry.
Connect patients, healthcare professionals and payors on a single platform.
Prevent future health complications and drive positive behavioural change.
In November 2020, a review published in the journal Cardiovascular Diabetology highlighted the renoprotective benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type-2 diabetes patients, over a spectrum of cardiovascular and renal risk profiles.
The annual European Society of Cardiology (ESC) Congress presents the latest scientific insights and innovations to a global audience.
Copyright by CaReMe Global Alliance 2022. All rights reserved.